To include your compound in the COVID-19 Resource Center, submit it here.

Ionis' IONIS-HTTRx reduces mutant HTT protein in Phase I/II for HD

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said IONIS-HTTRx (RG6042) significantly reduced mutant huntingtin (HTT) protein in the CSF of patients with early stage Huntington’s disease

Read the full 238 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE